Hims & Hers Health: Regulatory Tailwinds and Peptide Opportunity Support Buy Rating, $40 Price Target Reiterated
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Maria Ripps reiterated a Buy rating on Hims & Hers Health with a $40 price target, citing regulatory tailwinds and peptide opportunities. The Pharmacy Compounding Advisory Committee's support for compounding peptides like BPC-157 is viewed as a positive catalyst for market expansion. Despite monetization likely post-2027, Hims' manufacturing assets and infrastructure position it well in the estimated $13B–$26B peptide market. Barclays also maintained a Buy rating with a $39 target.
Analyst Maria Ripps of Canaccord Genuity maintained a Buy rating on Hims & Hers Health, retaining the price target of $40.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Maria Ripps has given his Buy rating due to a combination of factors that strengthen Hims & Hers Health’s long-term growth outlook. She views the Pharmacy Compounding Advisory Committee’s unexpected support for allowing peptides like BPC-157 and KPV to be compounded as a clear positive, reinforcing her thesis that regulatory reclassification can open a large new addressable market for the company. This early regulatory momentum, combined with Hims’s strong stock performance around the vote, supports maintaining a constructive stance and an unchanged $40 price target.
Ripps also highlights that, while formal FDA rulemaking will take time and any earnings contribution is unlikely before 2027, Hims is well positioned to capture future demand. The firm’s domestic manufacturing assets acquired from CSBio, its established 503A compounding infrastructure, and in-house testing capabilities are seen as key competitive advantages in winning share of an estimated $13B–$26B peptide market. Given these structural strengths and the favorable direction of early regulatory signals, she believes the risk/reward justifies a continued Buy rating despite the long lead time to monetization.
In another report released today, Barclays also maintained a Buy rating on the stock with a $39.00 price target.